Skip to main content

ONPATTRO (Alnylam Australia Pty Ltd)

Product name
ONPATTRO
Date registered
Evaluation commenced
Decision date
Approval time
157 (255 working days)
Active ingredients
patisiran
Registration type
NCE/NBE
Indication

ONPATTRO is indicated for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.

Registration process

Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.

Help us improve the Therapeutic Goods Administration site